Biocon Biologics

Biocon Biologics is the biosimilars-focused subsidiary of Biocon Limited, one of India's leading biopharmaceutical companies. Established as a dedicated vertical within the Biocon Group, it develops, manufactures and commercializes biosimilar versions of complex biologic medicines — including insulin, monoclonal antibodies and other recombinant proteins — with the aim of widening access to affordable biologics in India and across global markets. The company operates as part of Biocon's broader biopharmaceuticals business, which spans small-molecule active pharmaceutical ingredients, branded formulations and research services. Biocon Biologics is positioned at the premium, regulated-market end of that portfolio: it pursues development and regulatory filings in the United States and Europe while also serving emerging markets. Its product strategy centers on high-value biosimilar franchises in diabetes, oncology and immunology, areas where originator biologics are expensive and biosimilar competition can meaningfully lower treatment costs. Ownership sits with Biocon Limited, the listed parent whose shares trade on Indian exchanges. Biocon Biologics has attracted external strategic and financial investment to fund its biosimilar pipeline and global commercialization build-out, reflecting the capital-intensive nature of biologic development and manufacturing. The subsidiary operates manufacturing and R&D capacity tied to Biocon's broader science and technology infrastructure in India. As a brand, Biocon Biologics represents the group's ambition to be a global biosimilars player rather than only an API supplier — combining Indian cost advantages in biologics manufacturing with regulated-market quality standards. Its positioning emphasizes affordability, access and scientific credibility, and it competes in a global biosimilars field alongside established players in Europe, the United States and Asia.

Biocon Biologics emerged from Biocon Limited's strategic decision to build a dedicated biosimilars business rather than treat biologics as an extension of its established small-molecule API and formulations operations. Biocon, founded by Kiran Mazumdar-Shaw, had grown from an enzyme and API manufacturer into one of India's most prominent biopharmaceutical companies, and the biosimilars vertical was created to capture the global opportunity presented by patent expiries on major biologic drugs. The subsidiary was formally established in the mid-2010s as a distinct entity within the Biocon Group, allowing the parent to bring in external investors and to structure the capital-intensive biologics business separately. Biocon Biologics pursued a strategy of developing biosimilars for regulated markets — particularly the United States and Europe — while simultaneously commercializing in India and other emerging markets where affordability is a central policy concern. Its portfolio development focused on large-volume biologic categories: insulin for diabetes, and monoclonal antibodies in oncology and immunology. The company invested in manufacturing capacity and analytical characterization capabilities intended to meet the stringent comparability requirements of regulators such as the U.S. FDA and the European Medicines Agency. Partnerships and licensing arrangements with global pharmaceutical companies formed part of its commercialization model in various markets. Over time, Biocon Biologics attracted external equity investment, reflecting both the scale of capital required for biosimilar development and the strategic value investors placed on the franchise. It became a significant contributor to the Biocon Group's biopharmaceuticals segment and a flagship of India's ambition in the global biosimilars industry. The brand's history is thus closely intertwined with Biocon's broader transformation from an Indian API producer into an internationally oriented biopharmaceutical group.

• 2017

  External strategic investment brought into the biosimilars business to fund pipeline and global commercialization.

• 2014

  Biocon Biologics established as a dedicated biosimilars subsidiary within the Biocon Group.

Affordable, high-quality biosimilars for regulated and emerging markets, backed by Indian manufacturing scale and regulated-market quality standards.

• Diabetes

  Biosimilar insulin glargine

• Oncology

  Biosimilar trastuzumab

• Oncology

  Biosimilar bevacizumab

1. 1Biocon announces merger of its arm with Serum Institute subsidiary - BusinessTodaybusinesstoday.in
2. 2Biocon appoints MB Chinappa as CFO of Biocon Biologics- Moneycontrol.commoneycontrol.com
3. 3Biocon appoints Susheel Umesh as CCO, Emerging Marketsbiospectrumindia.com
4. 4Biocon Biologics launches Semglee, drug to control high blood sugar, in USeconomictimes.indiatimes.com
5. 5Biocon partners with Voluntis to develop digital therapeutics for diabetes patientseconomictimes.indiatimes.com
6. 6Biocon subsidiary acquires Pfizer's research facility - BusinessTodaybusinesstoday.in
7. 7Biocon subsidiary acquires research facility from Pfizer Healthcare- Moneycontrol.commoneycontrol.com
8. 8Biocon subsidiary buys Chennai-based research facility from Pfizer Healthcarethehindubusinessline.com
9. 9SII announces strategic partnership with Biocon Biologicsaninews.in